Use of pharmacogenomics in elderly patients treated for cardiovascular diseases
Croatian Medical Journal · 2020-04 · 61 (2) · 147-158
DOI: 10.3325/cmj.2020.61.147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Croatian Medical Journal, 2020-04. Verfasst von Nada Božina und 6 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref).
Abstract (Originalsprache)
Older people are increasingly susceptible to adverse drug reactions (ADRs) or therapeutic failure. This could be mediated by considerable polypharmacy, which increases the possibility of drug-drug and drug-gene interactions. Precision medicine, based on individual genetic variations, enables the screening of patients at risk for ADRs and the implementation of personalized treatment regimens. It combines genetic and genomic data with environmental and clinical factors in order to tailor prevention and disease-management strategies, including pharmacotherapy. The identification of genetic factors that influence drug absorption, distribution, metabolism, excretion, and action at the drug target level allows individualized therapy. Positive pharmacogenomic findings have been reported for the majority of cardiovascular drugs (CVD), suggesting that pre-emptive testing can improve efficacy and minimize the toxicity risk. Gene variants related to drug metabolism and transport variability or pharmacodynamics of major CVD have been translated into dosing recommendations. Pharmacogenetics consortia have issued guidelines for oral anticoagulants, antiplatelet agents, statins, and some beta-blockers. Since the majority of pharmacogenetics recommendations are based on the assessment of single drug-gene interactions, it is imperative to develop tools for the prediction of multiple drug-drug-gene interactions, which are common in the elderly with comorbidity. The availability of genomic testing has grown, but its clinical application is still insufficient.
Zitieren
APA
Božina, N., Kirhmajer, M. V., Šimičević, L., Ganoci, L., Skvrce, N. M., Domjanović, I. K., & Merćep, I. (2020). Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal, 61(2), 147-158. https://doi.org/10.3325/cmj.2020.61.147
Vancouver
Božina N, Kirhmajer MV, Šimičević L, Ganoci L, Skvrce NM, Domjanović IK, et al. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal. 2020;61(2):147-158. doi:10.3325/cmj.2020.61.147
BibTeX
@article{Boina2020,
author = {Božina, Nada and Kirhmajer, Majda Vrkić and Šimičević, Livija and Ganoci, Lana and Skvrce, Nikica Mirošević and Domjanović, Iva Klarica and Merćep, Iveta},
title = {Use of pharmacogenomics in elderly patients treated for cardiovascular diseases},
journal = {Croatian Medical Journal},
year = {2020},
volume = {61},
number = {2},
pages = {147--158},
doi = {10.3325/cmj.2020.61.147}
}
EUVIMED